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Abstract
·AIM: To evaluate the association between the size of
peripheral retinal non -perfusion and the number of
intravitreal ranibizumab injections in patients with
treatment -naive branch retinal vein occlusion (BRVO)
and macular edema.
·METHODS: A total of 53 patients with treatment-naive
BRVO and macular edema were included. Each patient
underwent a full ophthalmologic examination including
optical coherence tomography (OCT) imaging and ultra
wide -field fluorescein angiography (UWFA). Monthly
intravitreal ranibizumab injections were applied according
to the recommendations of the German Ophthalmological
Society. Two independent, masked graders quantified the
areas of peripheral retinal non-perfusion.
· RESULTS: Intravitreal injections improved best -
corrected visual acuity (BCVA) significantly from 22.23依
16.33 Early Treatment of Diabetic Retinopathy Study
(ETDRS) letters to 36.23 依15.19 letters ( <0.001), and
mean central subfield thickness significantly reduced
from 387依115 滋m to 321依115 滋m ( =0.01). Mean number
of intravitreal ranibizumab injections was 3.61依1.56. The
size of retinal non-perfusion correlated significantly with
the number of intravitreal ranibizumab injections ( =
0.724, <0.001).
· CONCLUSION: Peripheral retinal non -perfusion in
patients with BRVO associates significantly with
intravitreal ranibizumab injections in patients with BRVO
and macular edema.
·KEYWORDS: angiography; branch retinal vein occlusion;
non-perfusion; retina; wide-field
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INTRODUCTION
B ranch retinal vein occlusion (BRVO) is the second mostcommon major retinal vascular disease after diabetic
retinopathy[1]. The prevalence of BRVO has been estimated to
range from 0.6% to 1.1% [2-4]. The major risk factors for
BRVO include increasing age, hypertension, and concomitant
cardiovascular diseases [5-6]. The pathogenesis of BRVO is
believed to involve both retinal vein compression, by an
adjacent atherosclerotic artery, as well as damage to the
vessel wall through the trophic changes of venous
endothelium as well as intima or media possibly resulting in
thrombus formation [7]. BRVO may be asymptomatic or
associated with blurring in the visual field corresponding to
the involved retinal quadrant. Common vision-threatening
complications are cystoid macular edema, macular ischemia
and vitreous hemorrhage [8-9]. Macular edema is the most
common cause of visual loss in these patients, and intravitreal
injection of anti-vascular endothelial growth factor (anti-
VEGF) agents is one of the generally accepted and often used
treatment options. It has been suggested that the clinical
course of retinal vein occlusion may be affected by the extent
of retinal ischemia, including ischemia occurring in the
periphery[10].
Fluorescein angiography (FA) is able to determine whether
the vision loss is due to macular edema or ischemia [2]. On the
other hand, FA can also be an important tool to detect
peripheral ischemia. However, imaging of the peripheral
retina by common methods of FA is not optimal and often
accompanied by difficulties to depict peripheral
pathophysiological retinal alterations. This may be due to the
field of view of the traditional fundus cameras, which is
varying from 30 to 60 degrees; in addition, images of
different areas are not taken concurrently and comparison is
therefore not precise [11-12]. Furthermore, with traditional fundus
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cameras, the far periphery of the retina or the underlying
choroid cannot be visualized. With the advent of the
commercial ultra wide-field fluorescein angiography (UWFA;
Optos Panoramic 200; Optos PLC, Dunfermline, Scotland,
United Kingdom), simultaneous imaging of the posterior pole
and periphery of up to 200 degrees is possible[13-14].
The aims of this study were to investigate the relationship
between peripheral retinal non-perfusion in patients with
BRVO and macular edema and the number of intravitreal
injections using UWFA.
SUBJECTS AND METHODS
Patient Selection Fifty-three consecutive patients were
included in this prospective interventional study which was
conducted in the Department of Ophthalmology at Ludwig
Maximilians University, Munich, Germany between June 1,
2012 and February 1, 2014. The Institutional Review Board
approved the study design and patients' care was conformed
to the tenets of the World Medical Association Declaration of
Helsinki. All patients gave written informed consent for both
participation in the study and for FA. Inclusion criteria were
diagnosis of BRVO (as revealed by superficial hemorrhages
in a defined sector of the retina along a retinal vein) with
active macular edema. Center-involving macular edema was
defined and confirmed by macular leakage seen in FA and
central subfield thickness (CST) >250 滋m in cross-sectional
spectral-domain optical coherence tomography (SD-OCT)
images.
Patients without macular edema, previous focal or panretinal
photocoagulation and degenerative disorders of the posterior
pole and/or retinal periphery were excluded. Enrolled
patients received three intravitreal injections of 0.50 mg
ranibizumab (LucentisTM, Genentech, Inc., South San
Francisco, CA, USA and Novartis Pharma AG, Basel,
Switzerland) every four weeks according to the
recommendation of the German Ophthalmic Society.
Additional monthly injections were given at the presence of
retinal hemorrhage or macular edema as determined by
CST>250 滋m. All included patients had a thorough
ophthalmologic examination including visual acuity
evaluation using the Early Treatment of Diabetic Retinopathy
Study (ETDRS) refraction protocol, slit-lamp biomicroscopy,
applanation tonometry, indirect ophthalmoscopy and
SD-OCT before treatment and at each monthly follow-up
visit. UWFA was obtained for each patient before treatment.
Image Acquisition SD-OCT volume scans [20毅伊15毅 with
19 horizontal sections, automatic real time (ART) mean
value of 9, SD-OCT, Heidelberg Engineering, Heidelberg,
Germany] of the macula were obtained for each study eye to
measure the CST in 滋m by Heidelberg SD-OCT software,
double checked for accuracy and significant macular
ischemia was ruled out by UWFA. Ultra wide-field images
were acquired using the Optos 200Tx scanning laser
ophthalmoscope (Optos PLC) after standard intravenous
infusion of 5 mL of sodium fluorescein 10% by one
experienced technician for all included cases. Images were
taken of the posterior portion of the eye, and peripheral
images were taken in four cardinal directions (nasal, superior,
inferior, temporal).
Image Processing and Analysis Images were digitally
captured using the Optos V2 Vantage Review Software. This
allowed quality improvement and high resolution zoom for
the analysis of all acquired images. Images taken
approximately one minute (arteriovenous phase) and 4-5min
(late venous phase) after intravenous injection of fluorescein
were compressed into high-quality JPEG files ( Figures 1, 2)
and analysed for retinal non-perfusion by two experienced
ophthalmologists. For quantification of the non-perfused
areas, a standardized pattern grid with square fields of the
size of the optic disc was laid over the obtained images and
the non-perfused fields were counted (Figure 3). Retinal
non-perfusion was defined as hypofluorescence (representing
retinal non-perfusion or capillary dropout) or areas of
microvascular pathology (multiple microaneurysms and
significant perivascular leakage). In cases of extensive
intraretinal haemorrhage, the area of non-perfusion was
evaluated by comparing the UWFA images with the results of
the fundus examination.
Data Collection Collected parameters included number of
ischemic pattern fields of each included patient before
treatment, CST before and during therapy, demographic
information of all included patients, previous ocular history,
number and dates of intravitreal injections, best-corrected
visual acuity (BCVA) in ETDRS letters and intraocular
pressure throughout the observational period and the
occurrence of any complications. Regarding the quantified
peripheral retinal non-perfusion, all patients were divided
into two groups: 1) no peripheral retinal non-perfusion and a
mild to moderate peripheral retinal non-perfusion from 0 to
49 fields; 2) severe peripheral retinal non-perfusion from 50
to more than 100 fields of peripheral retinal non-perfusion.
Figure 1 En face wide-field fundus image of the right eye with
BRVO.
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Figure 2 Optos fluorescein angiogram of the same patient at arterio-venous (A) and late venous (B) phases The late phase image
reveals central fluorescein leakage inferior to the fovea and extensive areas of non-perfusion in the infero-temporal part of the peripheral
fundus.
Statistical Analysis Data were collected and analysed using
SPSS software (version 20.0, IBM Corporation, Armonk,
NY, USA). Each obtained variable was tested for normal
distribution. Nonparametric Mann-Whitney test was used
for ordinal variables. Spearman's rho test was used for
correlation analysis. A -value of < 0.05 was considered
statistically significant.
RESULTS
Mean age of all enrolled 53 treatment-naive BRVO with
center-involving macular edema was 71.18 依10.56y (range:
34-92y). Twenty-nine patients (55%) were male, twenty-four
(45% ) were right eyes. Four patients (7.5% ) had the
additional ophthalmic diagnosis of glaucoma, 35 patients
(66%) had systemic hypertension and 18 patients (34%) were
pseudophakic. Cut off time for follow-up was 18mo.
Regardless of peripheral perfusion status, mean BCVA was
22.23 依16.33 ETDRS letters and increased to 36.23 依15.19
letters after therapy ( <0.001). Mean CST was 387依115 滋m
and decreased to 321依115 滋m after treatment ( =0.01).
Mean number of intravitreal injections was 3.61依1.56 during
the study period. Table 1 shows the baseline and final
BCVA, CST and the number of intravitreal injections in each
group. The median number of intravitreal injections was
significantly different between the two study groups ( =0.001,
Mann-Whitney test). The size of retinal non-perfusion
correlated significantly with the number of intravitreal
ranibizumab injections ( =0.724, <0.001, Spearman's rho
test).
Panretinal photocoagulation was not performed during the
study because no case of anterior or posterior segment
neovascularization happened. Injection-related adverse events
such as retinal detachment or endophthalmitis did not occur.
DISCUSSION
Occlusion of a branch retinal vein results in leakage from the
capillary beds. A possible resulting irreversible damage of the
affected capillary beds in the retinal periphery may be
permanent non-perfusion of the retinal tissue with retinal
hypoxia causing the release of vasoproliferative chemicals
such as VEGF[15].
The relationship between peripheral retinal ischemia,
elevated VEGF levels and persistent macular edema is not
fully understood. It has been suggested that the clinical
course of retinal vein occlusion may be affected by the extent
of retinal ischemia, including ischemia occurring in the
periphery[10].
Since retinal ischemia is associated with higher levels of
VEGF, detecting the extent of the retinal non-perfusion is
important in patient management[16]. Little is known about the
Table 1 Baseline and final visual acuity, CST and the number of intravitreal injections for two groups with various extents of 
peripheral retinal non-perfusion 
Fields of peripheral 
retinal non-perfusion 
Baseline BCVA 
(ETDRS letters) 
Final BCVA 
(ETDRS letters) 
Baseline CST  
(µm) 
Final CST  
(µm) 
No. of intravitreal 
injections 
0-49 (n=25) 29.93±16.67 40.63±13.83 373±102 294±42 2.12±1.19 
50- >100 (n=28) 19.66±16.21 34.76±15.63 564±178 342±113 5.10±1.93 
P 0.02 0.01 <0.001 <0.001 0.001 
BCVA: Best-corrected visual acuity; CST: Central subfield thickness; ETDRS: Early Treatment of Diabetic Retinopathy Study. 
Figure 3 Quantification of the amount of non-perfused areas
using the grid with 27伊17 square fields approximately the size
of the optic disc.
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development of retinal peripheral non-perfusion because of
the limitation of available imaging technologies. A major
limitation of current studies is the difficulty to visualize the
peripheral fundus and pathophysiologic changes using the
common imaging devices.
UWFA is able to image the retina up to 200 degrees of the
ocular fundus [17-18]. By applying UWFA, we evaluated the
association between the frequency and amount of intravitreal
ranibizumab injections and the extent of non-perfused areas
in patients with BRVO and macular edema in the peripheral
retina. To our knowledge, this is the first study to apply an
invented grid for quantification of non-perfused areas of
UWFA in patients with BRVO. In this study, treatment with
ranibizumab resulted in a significant improvement in BCVA
and reduction in mean CST of the treated eyes. However,
patients with peripheral retinal non-perfusion received more
intravitreal injections for treatment of the macular edema.
In our study, baseline CST was significantly lower in patients
without peripheral retinal non-perfusion. Similar findings
have been reported by Singer [19]. They evaluated 32
patients with retinal vein occlusion and refractory macular
edema and found that mean CST was higher in patients with
more non-perfused areas. Prasad [10] investigated UWFA
angiograms from 80 eyes of 78 patients with a diagnosis of
BRVO (86% ) or hemi-central retinal vein occlusions
(CRVOs) (14% ). Untreated non-perfusion at any location
was associated with macular edema. They suggested that
areas of untreated retinal non-perfusion could be the source
of production of biochemical mediators that promote
neovascularization and macular edema. Campochiaro [20]
evaluated a total of 392 (397) patients with macular edema
due to CRVO and BRVO. Treatment with ranibizumab did
not worsen retinal non-perfusion in their patients. They
concluded that the initial vein occlusion is a precipitating
event resulting in ischemia and release of VEGF, which then
promotes the progression of retinal non-perfusion and
worsening of ischemia. They hypothesized that aggressive
blockade of VEGF prevents an exacerbation of retinal
non-perfusion, thus eliminating the positive feedback loop. In
a randomized clinical trial, Rehak [21] evaluated 22
patients with CRVO and suggested the selective laser
photocoagulation of peripheral areas of non-perfusion may
further improve the visual outcome and decrease the number
of ranibizumab re-injection in CRVO patients, not using
wide-field imaging in their study.
One limitation of our study was the relatively small number
of 53 patients, which is due to the fact that many patients are
being treated and followed up by office based
ophthalmologists. Another limitation was that we performed
UWFA for each patient at only a single time point, we were
not able to demonstrate potential angiographic changes
during the follow-up time.
In conclusion, UWFA is suitable to evaluate the peripheral
retina. In patients with BRVO and macular edema, the size of
retinal non-perfusion associates with applied intravitreal
ranibizumab injections. Further studies are needed to evaluate
whether treatment of peripheral non-perfused retina with
early peripheral photocoagulation may alter the number of
needed intravitreal injections.
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